22nd Century Group (XXII) Acquires GVB Biopharma May 13, 2022 09:17AM
22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis Company May 13, 2022 09:16AM
22nd Century Group (XXII) Granted FDA Approval for VLN as a Modified Risk Tobacco Product Dec 27, 2021 05:38AM
FDA Authorizes Marketing of 22nd Century Group’s VLN® as a Modified Risk Tobacco Product Dec 23, 2021 10:59PM
22nd Century Group (XXII) Confirms FDA Authorizes Marketing of its VLN as Modified Risk Tobacco Product Dec 23, 2021 11:47AM


Dec 23, 2021 11:46AM FDA Authorizes Marketing of 22nd Century Group’s VLN® as a Modified Risk Tobacco Product
Nov 15, 2021 09:20AM 22nd Century Group Applauds Califf Nomination as FDA Commissioner
Nov 4, 2021 06:00AM 22nd Century Group Reports Business Highlights and Financial Results for the Third Quarter 2021
Apr 15, 2021 05:56PM 22nd Century Stands Fully Prepared to Enable New Zealand Proposal to Advance Nationwide Smoke-Free Action Plan
Mar 11, 2021 07:00AM 22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020
Feb 24, 2021 10:00AM 22nd Century Group (XXII) Provides Business Update Letter from CEO
Feb 24, 2021 10:00AM 22nd Century Group Provides Business Update Letter from CEO
Jan 28, 2021 10:00AM 22nd Century Group to Relocate Headquarters to Buffalo’s Thriving Larkinville District
Jan 11, 2021 12:00PM 22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company’s Reduced Nicotine Content Cigarettes
Dec 8, 2020 10:01AM 22nd Century (XXII) Receives Order for 3.6 Million New SPECTRUM Variable Nicotine Cigarettes for U.S. Government-Supported Research
Dec 8, 2020 10:00AM 22nd Century Receives Order for 3.6 Million New SPECTRUM® Variable Nicotine Cigarettes for U.S. Government-Supported Research